ArticleAnimal models and experimental medicine2025
Bifidobacterium animalis subsp. lactis modulates early-life immune response and gut metabolism.
Article in Animal models and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Comparative Immunomodulatory Profiles ofJournal of microbiology and biotechnology · 2026Article
- A case-control analysis: changes in gut microbiota composition in children with autism spectrum disorder.Frontiers in microbiology · 2026Article
- Bifidobacterium animalis subsp. lactis modulates early-life immune response and gut metabolism.Animal models and experimental medicine · 2025Article
- Probiotics and human health: biological activities, nutritional aspects, immunomodulatory properties, applications, and future perspectives - a comprehensive review.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundThe maturation of the immune system is critical during early life, as it involves the differentiation, maturation, and establishment of immune tolerance of immune cells. This process is influenced not only by genetic factors but also by environmental factors, particularly the symbiotic microbiota. Bifidobacterium animalis subsp. lactis (BB-12), originally found in dairy products, is widely used in infant formula and dietary supplements. However, its role and mechanisms in immune development during early life remain unclear.
methodsUsing GF mice as the experimental model, B. animalis subsp. lactis BB-12 was administered via gavage during early life. In the juvenile stage, changes in T-cell subsets in the spleen, thymus, and gut intraepithelial lymphocytes (IEL) were assessed using spectral flow cytometry. Additionally, targeted metabolomics analysis of tryptophan metabolism and short-chain fatty acid pathways in colonic tissue was conducted to explore how B. animalis subsp. lactis BB-12 influences the immune system through gut microbiota metabolism.
resultsBB-12 effectively modulates the gut immune microenvironment, leading to beneficial changes in T-cell subsets in key immune tissues such as the spleen, thymus, and gut IELs. Metabolomics analysis further supports these findings by showing that BB-12 intervention greatly increased the production of tryptophan derivatives and acetic acid in the colon of GF mice.
conclusionThe findings provide theoretical evidence for the role of B. animalis subsp. lactis in immune system development and support its application in dietary supplements, suggesting potential as a component for infant immune health and in preventing immune-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.